Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2025-05-27 Regulatory Filings
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획승인신청등결정) (혈우병 치료신약 TU7710의 아르메니아 임상 1b상 시험계획(IND) 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the approval of a clinical trial (IND) for a drug candidate. Since this is a formal regulatory disclosure of a material event (clinical trial approval) and does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2025-05-27 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for TiumBio Co., Ltd. covering the period from January 1, 2025, to March 31, 2025. It contains detailed corporate information, capital structure, shareholding status, and business operations, which are characteristic of a comprehensive interim financial report. It is not a mere announcement or certification, as it provides substantive data. Q1 2025
2025-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure of insider transactions (purchases/sales of shares by directors or major shareholders). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2025-04-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically a decrease in stake due to fund liquidation and sales) by a major shareholder (Korea Investment Global Pharma-Ecosystem Private Equity Fund) and its special related parties in the company 'TiumBio'. This document is a mandatory disclosure of significant shareholding changes, which falls under the 'Major Shareholding Notification' category.
2025-04-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a mandatory regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including acquisition methods, funding sources, and contractual agreements. This falls under the 'Major Shareholding Notification' category.
2025-04-28 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow). It provides details such as the date, location, purpose, and contact information for the event. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate disclosure.
2025-04-23 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.